GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker

Imagem de Miniatura
Arquivos
art_CARVALHO_GLUT1_expression_in_malignant_tumors_and_its_use_2011.PDF (2.86 MB)
Citações na Scopus
175
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
CUNHA, Isabela W.
ROCHA, Rafael M.
AYALA, Fernanda R.
CAJAIBA, Mariana M.
BEGNAMI, Maria D.
VILELA, Rafael S.
PAIVA, Geise R.
ANDRADE, Rodrigo G.
SOARES, Fernando A.
Citação
CLINICS, v.66, n.6, p.965-972, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: To analyze glucose transporter 1 expression patterns in malignant tumors of various cell types and evaluate their diagnostic value by immunohistochemistry. INTRODUCTION: Glucose is the major source of energy for cells, and glucose transporter 1 is the most common glucose transporter in humans. Glucose transporter 1 is aberrantly expressed in several tumor types. Studies have implicated glucose transporter 1 expression as a prognostic and diagnostic marker in tumors, primarily in conjunction with positron emission tomography scan data. METHODS: Immunohistochemistry for glucose transporter 1 was performed in tissue microarray slides, comprising 1955 samples of malignant neoplasm from different cell types. RESULTS: Sarcomas, lymphomas, melanomas and hepatoblastomas did not express glucose transporter 1. Forty-seven per cent of prostate adenocarcinomas were positive, as were 29% of thyroid, 10% of gastric and 5% of breast adenocarcinomas. Thirty-six per cent of squamous cell carcinomas of the head and neck were positive, as were 42% of uterine cervix squamous cell carcinomas. Glioblastomas and retinoblastomas showed membranous glucose transporter 1 staining in 18.6% and 9.4% of all cases, respectively. Squamous cell carcinomas displayed membranous expression, whereas adenocarcinomas showed cytoplasmic glucose transporter 1 expression. CONCLUSION: Glucose transporter 1 showed variable expression in various tumor types. Its absence in sarcomas, melanomas, hepatoblastomas and lymphomas suggests that other glucose transporters mediate the glycolytic pathway in these tumors. The data suggest that glucose transporter 1 is a valuable immunohistochemical marker that can be used to identify patients for evaluation by positron emission tomography scan. The function of cytoplasmic glucose transporter 1 in adenocarcinomas must be further examined.
Palavras-chave
Glucose transporter 1, Immunohistochemistry, Protein expression, PET-scan, Malignant tumors
URI
https://observatorio.fm.usp.br/handle/OPI/24132
Referências
  1. Younes M, 1995, ANTICANCER RES, V15, P2895
  2. Reisser C, 1999, INT J CANCER, V80, P194
  3. Airley RE, 2007, CHEMOTHERAPY, V53, P233, DOI 10.1159/000104457
  4. Ciampi R, 2008, MOL CELL ENDOCRINOL, V291, P57, DOI 10.1016/j.mce.2008.05.003
  5. Fenske W, 2009, ENDOCR-RELAT CANCER, V16, P919, DOI 10.1677/ERC-08-0211
  6. Kang SS, 2002, JPN J CANCER RES, V93, P1123
  7. BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784
  8. Kawamura T, 2001, CANCER, V92, P634, DOI 10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X
  9. Chandler JD, 2003, CANCER, V97, P2035, DOI 10.1002/cncr.11293
  10. NISHIOKA T, 1992, CANCER RES, V52, P3972
  11. NAGASE Y, 1995, J UROLOGY, V153, P798, DOI 10.1016/S0022-5347(01)67725-5
  12. Bos R, 2002, J CLIN ONCOL, V20, P379, DOI 10.1200/JCO.20.2.379
  13. Yasuda M, 2005, ONCOL REP, V14, P1499
  14. Baer SC, 1997, J AM ACAD DERMATOL, V37, P575, DOI 10.1016/S0190-9622(97)70174-9
  15. Groves AM, 2011, EUR J NUCL MED MOL I, V38, P46, DOI 10.1007/s00259-010-1590-2
  16. Cantuaria G, 2001, CANCER, V92, P1144, DOI 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T
  17. Takanaga H, 2010, FASEB J, V24, P2849, DOI 10.1096/fj.09-146472
  18. Furuta E, 2010, BBA-REV CANCER, V1805, P141, DOI 10.1016/j.bbcan.2010.01.005
  19. Shanbhogue AKP, 2010, J COMPUT ASSIST TOMO, V34, P479, DOI 10.1097/RCT.0b013e3181db2670
  20. Avril N, 2001, J NUCL MED, V42, P9
  21. Dierckx RA, 2008, EUR J NUCL MED MOL I, V35, P1544, DOI 10.1007/s00259-008-0758-5
  22. Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
  23. YAMAMOTO T, 1990, BIOCHEM BIOPH RES CO, V170, P223, DOI 10.1016/0006-291X(90)91263-R
  24. Wachsberger PR, 2002, MELANOMA RES, V12, P35, DOI 10.1097/00008390-200202000-00006
  25. Brown RS, 2002, NUCL MED BIOL, V29, P443, DOI 10.1016/S0969-8051(02)00288-3
  26. Wang BY, 2000, CANCER, V88, P2774, DOI 10.1002/1097-0142(20000615)88:12<2774::AID-CNCR16>3.0.CO;2-I
  27. Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922
  28. Amann T, 2009, EXPERT OPIN THER TAR, V13, P1411, DOI 10.1517/14728220903307509
  29. WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
  30. Grabellus F, 2010, J NUCL MED, V51, P1191, DOI 10.2967/jnumed.110.075721
  31. Binder C, 1997, ANTICANCER RES, V17, P4299
  32. Rao UNM, 1999, MODERN PATHOL, V12, P1001
  33. Rudlowski C, 2003, AM J CLIN PATHOL, V120, P691, DOI 10.1309/4KYNQM5862JW2GD7
  34. Badi AN, 2009, INT J PEDIATR OTORHI, V73, P1187, DOI 10.1016/j.ijporl.2009.03.024
  35. Ogawa J, 1997, INT J CANCER, V74, P189, DOI 10.1002/(SICI)1097-0215(19970422)74:2<189::AID-IJC9>3.0.CO;2-V
  36. BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870
  37. Ayala FRR, 2010, MOLECULES, V15, P2374, DOI 10.3390/molecules15042374
  38. Thorens B, 2010, AM J PHYSIOL-ENDOC M, V298, pE141, DOI 10.1152/ajpendo.00712.2009
  39. Suganuma N, 2007, BJU INT, V99, P1143, DOI 10.1111/j.1464-410X.2007.06765.x
  40. Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2
  41. Nakajo M, 2012, EUR J RADIOL, V81, P146, DOI 10.1016/j.ejrad.2010.08.010
  42. BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X
  43. Chiche J, 2010, J CELL MOL MED, V14, P771, DOI 10.1111/j.1582-4934.2009.00994.x
  44. Haber RS, 1998, CANCER, V83, P34, DOI 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E
  45. North PE, 2000, HUM PATHOL, V31, P11, DOI 10.1016/S0046-8177(00)80192-6
  46. Minamimoto R, 2011, ANN NUCL MED, V25, P45, DOI 10.1007/s12149-010-0428-0
  47. Ravazoula P, 2003, EUR J GYNAECOL ONCOL, V24, P544
  48. Baer S, 2002, LARYNGOSCOPE, V112, P393, DOI 10.1097/00005537-200202000-00034
  49. Buim MEC, 2010, ORAL ONCOL, V46, P166, DOI 10.1016/j.oraloncology.2009.11.009
  50. De Jong IJ, 2010, Q J NUCL MED MOL IM, V54, P543
  51. Drut R, 2007, INT J SURG PATHOL, V15, P166, DOI 10.1177/1066896906299123
  52. FUKUMOTO H, 1988, DIABETES, V37, P657, DOI 10.2337/diabetes.37.5.657
  53. Hao Lang-Song, 2009, Sichuan Da Xue Xue Bao Yi Xue Ban, V40, P44
  54. Heber D, 1992, JPEN J PARENTER ENTE, V16, pS60, DOI 10.1177/014860719201600605
  55. HO CL, 2010, RADIOLOGY 1109, DOI 10.1148/RADIOL.10100672
  56. ISSELBAC.KJ, 1972, NEW ENGL J MED, V286, P929
  57. Jans J, 2010, UROLOGY, V75, P786, DOI 10.1016/j.urology.2009.08.024
  58. KALLINOWSKI E, 1989, CANCER RES, V49, P3759
  59. Khandani AH, 2009, ANN NUCL MED, V23, P595, DOI 10.1007/s12149-009-0264-2
  60. Kim YW, 2006, PATHOL RES PRACT, V202, P759, DOI 10.1016/j.prp.2006.07.006
  61. NORTH PE, 2001, ARCH DERMATOL, V137, P1
  62. OLIVER RJ, 2003, EUR J CANCER, V13, P503
  63. Smith TAD, 1999, BRIT J BIOMED SCI, V56, P285
  64. Stokkel MPM, 2002, J CANCER RES CLIN, V128, P393, DOI 10.1007/s00432-002-0350-5
  65. Storto G, 2010, BRIT J HAEMATOL, V151, P195, DOI 10.1111/j.1365-2141.2010.08335.x
  66. Usuda Katsuo, 2010, Gen Thorac Cardiovasc Surg, V58, P405, DOI 10.1007/s11748-010-0603-1
  67. Vander Heiden Matthew G, 2009, Science, V324, P1029, DOI 10.1126/science.1160809
  68. Vazquez A, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-58
  69. Wei Bo, 2009, Zhonghua Wei Chang Wai Ke Za Zhi, V12, P277

Coleções
Artigos e Materiais de Revistas Científicas - LIM/58